The use of MR imaging as an outcome measure in multiple sclerosis clinical trials.

[1]  V. Simnad.  Multiple Sclerosis Therapeutics, 3rd Edition , 2009 .

[2]  P M Matthews,et al.  Guidelines for using proton MR spectroscopy in multicenter clinical MS studies , 2007, Neurology.

[3]  Nick C Fox,et al.  Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates , 2007, Journal of neurology.

[4]  Jeffrey A. Cohen,et al.  Aspects of multiple sclerosis that relate to trial design and clinical management , 2007 .

[5]  S. Martínez-Yélamos,et al.  Regression to the mean in multiple sclerosis , 2006, Multiple sclerosis.

[6]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[7]  Ying Wu,et al.  Automated segmentation of multiple sclerosis lesion subtypes with multichannel MRI , 2006, NeuroImage.

[8]  R. Rudick,et al.  Significance of T2 lesions in multiple sclerosis: A 13‐year longitudinal study , 2006, Annals of neurology.

[9]  Anders M. Dale,et al.  Reliability of MRI-derived measurements of human cerebral cortical thickness: The effects of field strength, scanner upgrade and manufacturer , 2006, NeuroImage.

[10]  D. Arnold,et al.  Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis , 2006, Neurology.

[11]  D. Goodin.  Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: Have we been overly harsh in our assessment? , 2006, Annals of neurology.

[12]  Rohit Bakshi,et al.  Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis , 2006, Neurology.

[13]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[14]  Christian Confavreux,et al.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[15]  Rohit Bakshi,et al.  The measurement and clinical relevance of brain atrophy in multiple sclerosis , 2006, The Lancet Neurology.

[16]  Jiani Hu,et al.  Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis , 2005, Multiple sclerosis.

[17]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[18]  G. Comi,et al.  Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution , 2005, Neurology.

[19]  David H. Miller,et al.  Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis , 2005, Multiple sclerosis.

[20]  Rohit Bakshi,et al.  Regional lobar atrophy predicts memory impairment in multiple sclerosis. , 2005, AJNR. American journal of neuroradiology.

[21]  S. Atlas,et al.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.

[22]  Rohit Bakshi,et al.  The relationship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correction , 2005, NeuroImage.

[23]  Elizabeth Fisher,et al.  Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications , 2005, Multiple sclerosis.

[24]  A J Thompson,et al.  Gray and white matter volume changes in early RRMS , 2005, Neurology.

[25]  Robert Zivadinov,et al.  Reproducibility and Accuracy of Quantitative Magnetic Resonance Imaging Techniques of Whole‐Brain Atrophy Measurement in Multiple Sclerosis , 2005, Journal of Neuroimaging.

[26]  T. Waldmann,et al.  Erratum: Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β (Proceedings of the National Academy of Sciences of the United States of America (June 8, 2004) 101:23 (8705-8708)) , 2004 .

[27]  Marco Rovaris,et al.  Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[28]  Koen L. Vincken,et al.  Automatic segmentation of different-sized white matter lesions by voxel probability estimation , 2004, Medical Image Anal..

[29]  M. Rovaris,et al.  The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials , 2004, Multiple sclerosis.

[30]  R. Henry,et al.  Measurement of Whole‐Brain Atrophy in Multiple Sclerosis , 2004, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[31]  T. Waldmann,et al.  Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Alan J. Thompson,et al.  Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis , 2004, NeuroImage.

[33]  Massimo Filippi,et al.  Indirect evidence for early widespread gray matter involvement in relapsing–remitting multiple sclerosis , 2004, NeuroImage.

[34]  Jean-Philippe Ranjeva,et al.  Diffusion tensor imaging in multiple sclerosis: a tool for monitoring changes in normal-appearing white matter , 2004, Multiple sclerosis.

[35]  C. Pozzilli,et al.  The Relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis , 2004, Journal of Neurology.

[36]  A. Dale,et al.  Focal thinning of the cerebral cortex in multiple sclerosis. , 2003, Brain : a journal of neurology.

[37]  Massimo Filippi,et al.  The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis , 2003, The Lancet Neurology.

[38]  M Filippi,et al.  MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b , 2003, Neurology.

[39]  Rohit Bakshi,et al.  A semiautomated measure of whole-brain atrophy in multiple sclerosis , 2003, Journal of the Neurological Sciences.

[40]  P. M. Matthews,et al.  Evidence of early cortical atrophy in MS , 2003, Neurology.

[41]  Massimo Filippi,et al.  Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis , 2003, Journal of magnetic resonance imaging : JMRI.

[42]  F. Barkhof,et al.  The effect of interferon β-1b on quantities derived from MT MRI in secondary progressive MS , 2003, Neurology.

[43]  P. Matthews,et al.  Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis , 2003, Journal of Neurology.

[44]  Hans-Jochen Heinze,et al.  Sailer, M. et al. Focal thinning of the cerebral cortex in multiple sclerosis. Brain 126, 1734-1744 , 2003 .

[45]  A. Achiron,et al.  Brain MRI lesion load quantification in multiple sclerosis: a comparison between automated multispectral and semi-automated thresholding computer-assisted techniques. , 2002, Magnetic resonance imaging.

[46]  Stephen M. Smith,et al.  Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.

[47]  David H. Miller,et al.  Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. , 2002, Brain : a journal of neurology.

[48]  G. Scotti,et al.  Functional Magnetic Resonance Imaging Correlates of Fatigue in Multiple Sclerosis , 2002, NeuroImage.

[49]  Alan J Thompson,et al.  The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM‐based segmentation methodology , 2002, Journal of magnetic resonance imaging : JMRI.

[50]  B. Trapp,et al.  N‐acetylaspartate is an axon‐specific marker of mature white matter in vivo: A biochemical and immunohistochemical study on the rat optic nerve , 2002, Annals of neurology.

[51]  C. Good,et al.  A modified protocol to improve the detection of enhancing brain and spinal cord leasions in multiple sclerosis , 2001, Journal of Neurology.

[52]  G. Comi,et al.  Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments , 2001, Neurology.

[53]  Johan Montagnat,et al.  Automated Estimation of Brain Volume in Multiple Sclerosis with BICCR , 2001, IPMI.

[54]  P. Matthews,et al.  Normalized Accurate Measurement of Longitudinal Brain Change , 2001, Journal of computer assisted tomography.

[55]  S. Reingold,et al.  Placebo‐controlled clinical trials in multiple sclerosis: Ethical considerations , 2001, Annals of neurology.

[56]  R. Bakshi,et al.  Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. , 2001, Archives of neurology.

[57]  F. Barkhof,et al.  Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy , 2001, Journal of the Neurological Sciences.

[58]  J L Ostuni,et al.  Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis , 2001, Multiple sclerosis.

[59]  M Rovaris,et al.  Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis , 2001, Multiple sclerosis.

[60]  J. Simon.  Brain and Spinal Cord Atrophy in Multiple Sclerosis , 2000, CNS drugs.

[61]  G Cutter,et al.  Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients , 2000 .

[62]  Bruno Alfano,et al.  Automated segmentation and measurement of global white matter lesion volume in patients with multiple sclerosis , 2000 .

[63]  J. Frank,et al.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.

[64]  M Cercignani,et al.  Weekly diffusion-weighted imaging of normal-appearing white matter in MS , 2000, Neurology.

[65]  G J Barker,et al.  The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. , 2000, Brain : a journal of neurology.

[66]  J H Simon,et al.  A longitudinal study of T1 hypointense lesions in relapsing MS , 2000, Neurology.

[67]  S. Majumdar,et al.  Magnetization transfer ratio in new MS lesions before and during therapy with IFNβ-1a , 2000, Neurology.

[68]  Nick C Fox,et al.  Detection of ventricular enlargement in patients at the earliest clinical stage of MS , 2000, Neurology.

[69]  M Hutchinson,et al.  Quantitation of T2 lesion load in patients with multiple sclerosis: a novel semiautomated segmentation technique. , 2000, Academic radiology.

[70]  Caterina Mainero,et al.  Brain atrophy in relapsing-remitting multiple sclerosis: relationship with ‘black holes’, disease duration and clinical disability , 2000, Journal of the Neurological Sciences.

[71]  M Filippi,et al.  Cladribine and progressive MS , 2000, Neurology.

[72]  G. Comi,et al.  Pathologic damage in MS assessed by diffusion-weighted and magnetization transfer MRI , 2000, Neurology.

[73]  J K Udupa,et al.  Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. , 2000, Radiology.

[74]  M N Rossor,et al.  Progressive cerebral atrophy in MS , 2000, Neurology.

[75]  L. Kappos,et al.  The use of magnetic resonance imaging in multiple sclerosis treatment trials: power calculations for annual lesion load measurement , 2000, Journal of Neurology.

[76]  F. Barkhof,et al.  Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability , 1999, Annals of neurology.

[77]  R. Rudick,et al.  Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.

[78]  Jeffrey A. Cohen,et al.  Multiple Sclerosis Therapeutics , 1999 .

[79]  G. Barker,et al.  Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H , 1999, Neurology.

[80]  Jacqueline Palace,et al.  The effect of anti-α4 integrin antibody on brain lesion activity in MS , 1999, Neurology.

[81]  D. Paty,et al.  Magnetic resonance imaging results of the PRISMS trial: A randomized, double‐blind, placebo‐controlled study of interferon‐β1a in relapsing‐remitting multiple sclerosis , 1999 .

[82]  F. Barkhof,et al.  Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results , 1999, Journal of neurology, neurosurgery, and psychiatry.

[83]  Ludwig Kappos,et al.  Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis , 1999, The Lancet.

[84]  M Filippi,et al.  Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI , 1999, Neurology.

[85]  M Filippi,et al.  Interscanner variation in brain MR lesion load measurements in multiple sclerosis using conventional spin-echo, rapid relaxation-enhanced, and fast-FLAIR sequences. , 1999, AJNR. American journal of neuroradiology.

[86]  M. Horsfield,et al.  A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. , 1998, Brain : a journal of neurology.

[87]  G. Barker,et al.  Spinal cord atrophy and disability in MS , 1998, Neurology.

[88]  J K Udupa,et al.  Comparison of T2 lesion volume and magnetization transfer ratio histogram analysis and of atrophy and measures of lesion burden in patients with multiple sclerosis. , 1998, AJNR. American journal of neuroradiology.

[89]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[90]  F. Barkhof,et al.  Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. , 1998, AJNR. American journal of neuroradiology.

[91]  F. Barkhof,et al.  Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis , 1998, Annals of neurology.

[92]  R. Tarducci,et al.  1H-MRS in patients with multiple sclerosis undergoing treatment with interferon β-1a: results of a preliminary study , 1998, Journal of neurology, neurosurgery, and psychiatry.

[93]  G. Barker,et al.  Quantitative techniques for lesion load measurement in multiple sclerosis: an assessment of the global threshold technique after non uniformity and histogram matching corrections , 1998, European journal of neurology.

[94]  P M Matthews,et al.  Imaging axonal damage of normal-appearing white matter in multiple sclerosis. , 1998, Brain : a journal of neurology.

[95]  M. Horsfield,et al.  The influence of clinical relapses and steroid therapy on the development of Gd‐enhancing lesions: a longitudinal MRI study in relapsing—remitting multiple sclerosis patients , 1997, Acta neurologica Scandinavica.

[96]  P M Matthews,et al.  Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. , 1996, Brain : a journal of neurology.

[97]  M Filippi,et al.  Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS , 1996, Neurology.

[98]  P. S. Albert,et al.  Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis , 1995, Neurology.

[99]  D. Li,et al.  Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis , 1994, Annals of neurology.

[100]  J. Taubenberger,et al.  Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis , 1993, Annals of neurology.

[101]  H. McFarland,et al.  Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine–enhancing magnetic resonance imaging lesions , 1993, Annals of neurology.

[102]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[103]  R. Hirsch,et al.  Treatment of multiple sclerosis with gamma interferon , 1987, Neurology.